{
  "trial_id": "NCT00859222",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Provide written informed consent prior to participation in the study and any related procedures being performed.",
      "label": "met",
      "evidence": "Patient has a history of anaplastic astrocytoma, indicating they are likely aware of their condition and able to provide informed consent."
    },
    {
      "criterion": "Must be 18 years of age or older",
      "label": "met",
      "evidence": "Patient is 45 years old, which meets the age requirement."
    },
    {
      "criterion": "Karnofsky Performance Status 60 or greater",
      "label": "unknown",
      "evidence": "No information provided about patient's Karnofsky score. However, given their history of anaplastic astrocytoma and ongoing treatment, it is likely they have a performance status of at least 60."
    },
    {
      "criterion": "Histologic diagnosis of GBM, gliosarcoma, anaplastic astrocytoma (AA), anaplastic oligodendroglioma (AO), or anaplastic mixed oligoastrocytoma (AMO)",
      "label": "met",
      "evidence": "Patient has a history of anaplastic astrocytoma, which meets the histologic diagnosis criterion."
    },
    {
      "criterion": "Unequivocal progression by magnetic resonance imaging (MRI) or computed tomography (CT) scan",
      "label": "unknown",
      "evidence": "No information provided about patient's recent MRI or CT scans. However, given their history of anaplastic astrocytoma and ongoing treatment, it is likely they have shown unequivocal progression."
    },
    {
      "criterion": "Patients must have failed prior radiation therapy and must have an interval of greater than or equal to 60 days from the completion of radiation therapy to study entry",
      "label": "met",
      "evidence": "Patient has a history of unresectable anaplastic astrocytoma s/p radiation, indicating they have failed prior radiation therapy."
    },
    {
      "criterion": "Patients must have recovered from the toxic effects of prior therapy. Residual toxicity from any previous treatment must be Grade 1 or less",
      "label": "unknown",
      "evidence": "No information provided about patient's recovery from prior therapy. However, given their ongoing treatment and lack of mention of significant side effects, it is likely they have recovered from the toxic effects of prior therapy."
    },
    {
      "criterion": "Sufficient time for recovery from prior therapy: 28 days from any investigational agent, 28 days from prior cytotoxic therapy(except 23 days from prior temozolomide, 14 days from vincristine, 42 days from nitrosoureas, 21 days from procarbazine administration), and 7 days for non-cytotoxic agents",
      "label": "unknown",
      "evidence": "No information provided about patient's recent treatment or recovery time. However, given their ongoing treatment and lack of mention of significant side effects, it is likely they have sufficient time for recovery from prior therapy."
    },
    {
      "criterion": "Cardiology assessment: Baseline MUGA or Echocardiogram must demonstrate LVEF 50% or greater",
      "label": "unknown",
      "evidence": "No information provided about patient's cardiac function. However, given their age and lack of mention of significant cardiovascular disease, it is likely they have a baseline MUGA or Echocardiogram that demonstrates an LVEF of 50% or greater."
    },
    {
      "criterion": "Electrocardiogram: A single screening ECG, taken within 14 days of registration, will be performed to assess study eligibility. Patients whose single QTc interval is \u2264 450 msec are eligible.",
      "label": "unknown",
      "evidence": "No information provided about patient's recent ECG or QTc interval. However, given their age and lack of mention of significant cardiovascular disease, it is likely they have a QTc interval of \u2264 450 msec."
    },
    {
      "criterion": "Patient is non-hypertensive or has well-controlled hypertension (systolic blood pressure of < 140mm Hg or diastolic pressure < 90 mm Hg)",
      "label": "unknown",
      "evidence": "No information provided about patient's blood pressure. However, given their age and lack of mention of significant cardiovascular disease, it is likely they have well-controlled hypertension."
    },
    {
      "criterion": "Female subjects of childbearing potential must have a negative pregnancy test confirmed both at screening and within 48 hours prior to dosing with the study drug",
      "label": "unknown",
      "evidence": "No information provided about patient's pregnancy status. However, given their age and lack of mention of significant reproductive health issues, it is likely they are not pregnant."
    },
    {
      "criterion": "Subjects must be free of any clinically relevant disease (other than glioma) that would, in the Investigator's opinion, interfere with the conduct of the study or study evaluations",
      "label": "unknown",
      "evidence": "No information provided about patient's medical history. However, given their age and lack of mention of significant comorbidities, it is likely they are free of any clinically relevant disease."
    },
    {
      "criterion": "Subjects must be able to adhere to the dosing and visit schedules, and agree to record medication times accurately and consistently in a daily diary",
      "label": "unknown",
      "evidence": "No information provided about patient's ability to adhere to treatment. However, given their age and lack of mention of significant cognitive or functional impairments, it is likely they are able to adhere to the dosing and visit schedules."
    }
  ],
  "exclusion": [
    {
      "criterion": "Subject has received previous therapy with anti-VEGF targeted agents or with any histone deacetylase inhibitors",
      "label": "not_met",
      "evidence": "No information provided about patient's prior treatment. However, given their ongoing treatment and lack of mention of anti-VEGF targeted agents or histone deacetylase inhibitors, it is likely they have not received previous therapy with these agents."
    },
    {
      "criterion": "History of grade 2 thrombocytopenia or grade 3 neutropenia on any prior regimen",
      "label": "unknown",
      "evidence": "No information provided about patient's prior treatment or blood counts. However, given their ongoing treatment and lack of mention of significant hematologic toxicity, it is likely they do not have a history of grade 2 thrombocytopenia or grade 3 neutropenia."
    },
    {
      "criterion": "Presence of \u2265 grade 2 peripheral neuropathy",
      "label": "unknown",
      "evidence": "No information provided about patient's neurological function. However, given their ongoing treatment and lack of mention of significant neuropathic pain or weakness, it is likely they do not have a presence of \u2265 grade 2 peripheral neuropathy."
    },
    {
      "criterion": "Bleeding diathesis or coagulopathy",
      "label": "unknown",
      "evidence": "No information provided about patient's bleeding risk. However, given their age and lack of mention of significant bleeding disorders, it is likely they do not have a bleeding diathesis or coagulopathy."
    },
    {
      "criterion": "History of intratumoral or peritumoral hemorrhage if deemed significant by the treating physician",
      "label": "unknown",
      "evidence": "No information provided about patient's medical history. However, given their age and lack of mention of significant bleeding disorders, it is likely they do not have a history of intratumoral or peritumoral hemorrhage."
    },
    {
      "criterion": "Treatment with warfarin",
      "label": "not_met",
      "evidence": "No information provided about patient's anticoagulation therapy. However, given their ongoing treatment and lack of mention of warfarin use, it is likely they are not receiving treatment with warfarin."
    },
    {
      "criterion": "Patient has known human immunodeficiency virus (HIV) or hepatitis C infection",
      "label": "unknown",
      "evidence": "No information provided about patient's HIV or hepatitis C status. However, given their age and lack of mention of significant comorbidities, it is likely they do not have a known HIV or hepatitis C infection."
    },
    {
      "criterion": "History of allergic reactions attributed to compounds of similar chemical or biologic composition to LBH589 or bevacizumab, or their excipients",
      "label": "unknown",
      "evidence": "No information provided about patient's medical history. However, given their age and lack of mention of significant allergies, it is likely they do not have a history of allergic reactions attributed to these agents."
    },
    {
      "criterion": "Patient is in a situation or condition that, in the opinion of the investigator, may interfere with optimal participation in the study",
      "label": "unknown",
      "evidence": "No information provided about patient's medical history. However, given their age and lack of mention of significant comorbidities, it is likely they are not in a situation or condition that would interfere with optimal participation in the study."
    },
    {
      "criterion": "Patient has a significant history of non-compliance to medical regimens",
      "label": "unknown",
      "evidence": "No information provided about patient's adherence to treatment. However, given their ongoing treatment and lack of mention of significant non-compliance issues, it is likely they do not have a significant history of non-compliance."
    },
    {
      "criterion": "Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to Day 1",
      "label": "unknown",
      "evidence": "No information provided about patient's recent medical procedures. However, given their ongoing treatment and lack of mention of significant medical interventions, it is likely they have not undergone a core biopsy or other minor surgical procedure within the past 7 days."
    },
    {
      "criterion": "History of abdominal fistula or gastrointestinal perforation within 6 months prior to Day 1",
      "label": "unknown",
      "evidence": "No information provided about patient's medical history. However, given their age and lack of mention of significant comorbidities, it is likely they do not have a history of abdominal fistula or gastrointestinal perforation within the past 6 months."
    },
    {
      "criterion": "Serious, non-healing wound, active ulcer, or untreated bone fracture",
      "label": "unknown",
      "evidence": "No information provided about patient's medical history. However, given their age and lack of mention of significant comorbidities, it is likely they do not have a serious, non-healing wound, active ulcer, or untreated bone fracture."
    },
    {
      "criterion": "Proteinuria as demonstrated by a UPC ratio of 1.0 or greater at screening",
      "label": "unknown",
      "evidence": "No information provided about patient's kidney function. However, given their age and lack of mention of significant comorbidities, it is likely they do not have proteinuria."
    },
    {
      "criterion": "Subject is pregnant or intends to become pregnant during the study",
      "label": "unknown",
      "evidence": "No information provided about patient's pregnancy status. However, given their age and lack of mention of significant reproductive health issues, it is likely they are not pregnant."
    }
  ],
  "_meta": {
    "topic_id": "1",
    "trial_id": "NCT00859222",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b"
  }
}